Risankizumab improves long-term outcomes in patients with palmoplantar pustulosis: Study
A new study published in The Journal of Dermatology revealed that patients with palmoplantar pustulosis (PPP) who were 18 years of age or older who received risankizumab therapy saw long-lasting improvements in their disease's signs and symptoms, and their safety profile was similar with previous safety findings from other psoriasis risankizumab trials.
Palmoplantar pustulosis is typified by recurrent flare-ups and remissions and mostly affects women, and patients frequently have a history of localized infection and smoking. According to estimates, the prevalence of PPP in the Japanese population is 0.12%, greater than that of other affluent nations. Up to 30% of individuals with PPP (mostly women) have pustulotic arthro-osteitis (PAO) which is a serious comorbidity.
A humanized immunoglobin G1 monoclonal antibody called risankizumab (RZB) binds to the p19 component of IL-23 to selectively block it. Psoriatic arthritis, psoriasis vulgaris, erythrodermic psoriasis, generalized pustular psoriasis, and PPP in adults are among the conditions for which it is authorized in Japan. From the JumPPP research, this investigation was set to assess RZB in adult Japanese subjects with moderate-to-severe palmoplantar pustulosis.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.